|25th September 2020||Garo H Armen||3,676||Grant/award etc.||$4.02||$14,777.52|
|11th September 2020||Garo H Armen||2,962||Grant/award etc.||$4.99||$14,780.38|
|28th August 2020||Garo H Armen||3,452||Grant/award etc.||$4.28||$14,774.56|
|14th August 2020||Garo H Armen||3,984||Grant/award etc.||$3.71||$14,780.64|
|31st July 2020||Garo H Armen||4,861||Grant/award etc.||$3.04||$14,777.44|
|17th July 2020||Garo H Armen||4,105||Grant/award etc.||$3.60||$14,778.00|
|2nd July 2020||Garo H Armen||3,676||Grant/award etc.||$4.02||$14,777.52|
|19th June 2020||Ulf Wiinberg||20,338||Exercise of derivative||$0.00|
|19th June 2020||Timothy Wright||20,338||Exercise of derivative||$0.00|
|19th June 2020||Garo H Armen||3,859||Grant/award etc.||$3.83||$14,779.97|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Agenus, Inc. engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.